JP2021528368A5 - - Google Patents

Info

Publication number
JP2021528368A5
JP2021528368A5 JP2020562120A JP2020562120A JP2021528368A5 JP 2021528368 A5 JP2021528368 A5 JP 2021528368A5 JP 2020562120 A JP2020562120 A JP 2020562120A JP 2020562120 A JP2020562120 A JP 2020562120A JP 2021528368 A5 JP2021528368 A5 JP 2021528368A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
heterocyclyl
heteroaryl
sulfo
Prior art date
Application number
JP2020562120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528368A (ja
JPWO2019217933A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031885 external-priority patent/WO2019217933A1/en
Publication of JP2021528368A publication Critical patent/JP2021528368A/ja
Publication of JPWO2019217933A5 publication Critical patent/JPWO2019217933A5/ja
Publication of JP2021528368A5 publication Critical patent/JP2021528368A5/ja
Priority to JP2024022691A priority Critical patent/JP2024056937A/ja
Pending legal-status Critical Current

Links

JP2020562120A 2018-05-10 2019-05-10 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 Pending JP2021528368A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022691A JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669926P 2018-05-10 2018-05-10
US62/669,926 2018-05-10
PCT/US2019/031885 WO2019217933A1 (en) 2018-05-10 2019-05-10 Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022691A Division JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021528368A JP2021528368A (ja) 2021-10-21
JPWO2019217933A5 JPWO2019217933A5 (https=) 2022-05-17
JP2021528368A5 true JP2021528368A5 (https=) 2022-05-17

Family

ID=68467113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562120A Pending JP2021528368A (ja) 2018-05-10 2019-05-10 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Country Status (10)

Country Link
US (1) US12582660B2 (https=)
EP (1) EP3790541B1 (https=)
JP (2) JP2021528368A (https=)
KR (1) KR20210009331A (https=)
CN (1) CN112312901B (https=)
AU (1) AU2019265011B2 (https=)
CA (1) CA3099148A1 (https=)
IL (1) IL278596B2 (https=)
MX (1) MX2020011991A (https=)
WO (1) WO2019217933A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112312901B (zh) 2018-05-10 2024-05-14 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233051A (ja) 1984-05-04 1985-11-19 Daicel Chem Ind Ltd 2−クロル−5−ニトロベンゼンスルホンアミドの製造方法
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
CN1145608C (zh) * 1998-06-09 2004-04-14 诺特兰药品有限公司 作为镇咳剂的季铵化合物
US20080139534A1 (en) 2006-12-07 2008-06-12 Xavier University Of Louisiana Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis
US7951806B2 (en) * 2007-07-25 2011-05-31 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
FR2925495B1 (fr) * 2007-12-21 2010-09-10 Pf Medicament Derives dimeriques d'artemisinine et application en therapie anticancereuse
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CN101919842A (zh) 2009-06-11 2010-12-22 复旦大学 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用
US8557980B2 (en) 2010-02-18 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for forming protected organoboronic acids
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
KR20120048223A (ko) 2010-11-05 2012-05-15 주식회사 이큐스앤자루 2-페닐-4-[3-(치환된-설포닐)아닐리노]퀴나졸린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 c형 간염의 예방 또는 치료용 약학적 조성물
GB201020397D0 (en) 2010-12-02 2011-01-12 Univ Nottingham Compounds
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
WO2014037726A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Liquid pharmaceutical compositions
ES2491390B1 (es) * 2013-02-04 2015-06-22 Universidad Complutense De Madrid Nuevos inhibidores de la enzima isoprenilcisteina carboximetiltransferasa (icmt)
EP2984088B1 (en) 2013-04-12 2019-03-20 Asana BioSciences, LLC Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20160168108A1 (en) * 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
CA3017211A1 (en) 2016-03-16 2017-09-21 Endocyte, Inc. Carbonic anhydrase ix inhibitor conjugates and uses thereof
CN112312901B (zh) 2018-05-10 2024-05-14 路易斯维尔大学研究基金会有限公司 Ras癌蛋白抑制剂及其制备方法和使用方法

Similar Documents

Publication Publication Date Title
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
RU2672575C2 (ru) Лечение рака головного мозга
ES2360125T3 (es) Formulación farmacéutica de decitabina.
JP2012529486A5 (https=)
JPWO2020053655A5 (https=)
JP2014132009A5 (https=)
JP2021528368A5 (https=)
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CN111012785B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途
JP2019517587A5 (https=)
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
JP2018513130A (ja) Hsp90阻害ペプチド結合体及びその腫瘍治療における応用
JP2020510075A5 (https=)
JP2012525411A5 (https=)
RU2020131402A (ru) 4-метилдигидропиримидиноновые соединения и их применение в фармацевтике
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2014530204A5 (https=)
CN1181819C (zh) 使用五氟苯磺酰胺的综合疗法
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
JP2007530692A (ja) 6−メルカプトプリンの改良された製剤
EP2394642A1 (en) 5-ALA ester formulations and use thereof
JPWO2019217933A5 (https=)
MX2022004610A (es) Uso de derivado de fenilquinolinona o derivado flavonoide para tratamiento del dolor neuropático.
RU2010118458A (ru) Производное изоксазола для лечения рака